Pharming Group (NASDAQ:PHAR) Given “Buy” Rating at HC Wainwright

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $37.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 323.34% from the company’s current price.

PHAR has been the subject of a number of other research reports. Jefferies Financial Group assumed coverage on shares of Pharming Group in a research report on Monday. They issued a “buy” rating and a $14.00 target price for the company. Oppenheimer lowered their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th.

Pharming Group Trading Up 5.8 %

Pharming Group stock opened at $8.74 on Wednesday. Pharming Group has a 52-week low of $6.65 and a 52-week high of $13.20. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $592.88 million, a price-to-earnings ratio of -33.62 and a beta of 0.05. The firm has a 50-day moving average price of $8.21 and a two-hundred day moving average price of $8.13.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR) by 75.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 41,110 shares of the company’s stock after acquiring an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.